CTLs directed against HER2 specifically cross-react with HER3 and HER4

Journal of Immunology

Volumn 180, Issue 12, 2008, Pages 8135-8145

  Conrad, Heinke ^a,b   Gebhard, Kerstin ^a,b   Kronig, Holger ^a   Neudorfer, Julia ^a   Busch, Dirk H ^a,b   Peschel, Christian ^a   Bernhard, Helga ^a,b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EPITOPE; GAMMA INTERFERON; HLA A ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERBB2 PROTEIN, HUMAN; HER 2 PEPTIDE E75 (369 377), HUMAN; HER-2 PEPTIDE E75 (369-377), HUMAN; HLA A2 ANTIGEN; PEPTIDE FRAGMENT;

ANTIGEN PRESENTATION; ARTICLE; CELL CLONE; CELL MEDIATED CYTOTOXICITY; CROSS REACTION; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SEQUENCE HOMOLOGY; TUMOR CELL; TUMOR CELL DESTRUCTION; UPREGULATION; CELL STRAIN K 562; CYTOTOXICITY TEST; IMMUNOLOGY; METABOLISM; PROTEIN BINDING; TUMOR CELL LINE;

ANTIGEN PRESENTATION; CELL LINE, TUMOR; CLONE CELLS; CYTOTOXICITY TESTS, IMMUNOLOGIC; EPITOPES, T-LYMPHOCYTE; HLA-A2 ANTIGEN; HUMANS; IMMUNODOMINANT EPITOPES; K562 CELLS; PEPTIDE FRAGMENTS; PROTEIN BINDING; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; T-LYMPHOCYTES, CYTOTOXIC;

EID: 50949133930     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.12.8135     Document Type: Article

References (76)

1. Lee, K.-F., H. Simon, H. Chen, B. Bates, M.-C. Hung, and C. Hauser. 1995. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 378: 394-398.
2. Gassmann, M., F. Casagranda, D. Orioli, H. Simon, C. Lai, R. Klein, and G. Lemke. 1995. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature 378: 390-394.
3. DiGiovanna, M. P., P. Chu, T. L. Davison, C. L. Howe, D. Carter, E. B. Claus, and D. F. Stern. 2002. Active signaling by HER-2/neu in a subpopulation of HER2/ncu-overexpressing ductal carcinoma in situ: clinicopathological correlates. Cancer Res. 62: 6667-6673.
4. Slamon, D. J., G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich, and W. L. McGuire. 1987. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu Oncogene. Science 235: 177-182.
5. Witton, C. J., J. R. Reeves, J. J. Going, T. G. Cooke, and J. M. Bartlett. 2003. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J. Pathol. 200: 290-297.
6. Holbro, T., R. R. Beerli, F. Maurer, M. Koziczak, C. F. Barbas, and N. E. Hynes. 2003. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc. Natl. Acad. Sci. USA 100: 8933-8938.
7. Alimandi, M., A. Romano, M. C. Curia, R. Muraro, P. Fedi, S. A. Aaronson, P. P. DiFiore, and M. H. Kraus. 1995. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 4: 1813-1821.
8. Siegel, P. M., E. D. Ryan, R. D. Cardiff, and W. J. Muller. 1999. Elevated expression of activated forms of NEU/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J. 18: 2149-2164.
9. Guy, C. T., M. A. Webster, M. Schaller, T. J. Parsons, R. D. Cardiff, and W. J. Muller. 1992. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl. Acad. Sci. USA 89: 10578-10582.
10. Hynes, N. E., and H. A. Lane. 2005. ErbB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. 5: 341-354.
11. Bemhard, H., K. L. Knutson, L. Salazarm, K. Schiffman, and M. L. Disis. 2002. Vaccination against the HER-2/neu oncogenic protein. Endocr. Relal. Cancer 9: 33-44.
12. Slamon, D. J., B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, A. Bajamonde, T. Fleming, W. Eiermann, J. Wolter, M. Pegram, et al. 2001. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344: 783-792.
13. Vogel, C. L., M. A. Cobleigh, D. Tripathy, J. C. Gutheil, L. N. Harris, L. Fehrenbacher, D. J. Slamon, M. Murphy, W. F. Novotny, M. Burchmore, et al. 2002. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20: 719-726.
14. Piccart-Gebhart, M. J., M. Procter, B. Leyland-Jones, A. Goldhirsch, M. Untch, I. Smith, L. Gianni, J. Baselga, R. Bell, C. Jackisch, et al. 2005. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353: 1659-1672.
15. Romond, E. H., E. A. Perez, J. Bryant, V. J. Suman, C. E. Geyer, N. E. Davidson, E. Tan-Chiu, S. Martino, S. Paik, P. A. Kaufman, et al. 2005. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353: 1673-1684.
16. Disis, M. L., T. A. Gooley, K. Rinn, D. Davis, M. Piepkom, M. A. Cheever, K. L. Knutson, and K. Schiffman. 2002. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J. Clin. Oncol. 20: 2624-2632.
17. Disis, M. L., K. Schiffman, K. Guthrie, L. G. Salazar, K. L. Knutson, V. Goodell, C. dela Rosa, and M. A. Cheever. 2004. Effect of dose on immune response in patients vaccinated with an HER-2/neu intracellular domain protein-based vaccine. J. Clin. Oncol. 22: 1916-1925.
18. Peoples, G. E., J. M. Gurney, M. T. Hucman, M. M. Woll, G. B. Ryan, C. E. Storrer, C. Fisher, C. D. Shriver, C. G. loannides, and S. Ponniah. 2005. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J. Clin. Oncol. 23: 7536-7545.
19. + hemopoietic progenitor cells. J. Immunol. 165: 4133-4140.
20. Meyer zum Buschenfelde, C., J. Metzger, C. Hermann, N. Nicklisch, C. Peschel, and H. Bernhard. 2001. The generation of both T killer and T helper cell clones specific for the tumor-associated antigen HER2 using retrovirally transduced dendritic cells. J. Immunol. 167: 1712-1719.
21. + T cells or CTL immunothcrapy of tumors expressing the antigen. J. Immunol. 166: 2863-2870.
22. + T cells for use in adoptive immuno-therapy of established tumors. Nat. Med. 12: 335-341.
23. Dudley, M. E., J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, R. Sherry, N. P. Restifo, A. M. Hubicki, et al. 2002. Cancer regression and autoimmunity in patients after clonal repopu-lation with antitumor lymphocytes. Science 298: 850-854.
24. + T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. USA 99: 16168-16173.
25. Meidenbauer, N., J. Marienhagen, M. Laumer, S. Vogl, J. Heymann, R. Andreesen, and A. Mackensen. 2003. Survival and tumor localization of adoptively transferred melan-A-specific T cells in melanoma patients. J. Immunol. 170: 2161-2169.
26. Bollard, C. M., L. Aguilar, K. C. Straathof, B. Gahn, M. H. Huls, A. Rousseau, J. Sixbey, M. V. Gresik, G. Carrum, M. Hudson, et al. 2004. Cytotoxic T lymphocyte therapy for Epstein-Barr virus Hodgkin's disease. J. Exp. Med. 200: 1623-1633.
27. Comoli, P., P. Pedrazzoli, R. Maccario, S. Basso, O. Carminati, M. Labirio, R. Schiavo, S. Secondino, C. Frasson, C. Perotti, et al. 2005. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J. Clin. Oncol. 23: 8942-8949.
28. Vignard, V., B. Lemercier, A. Lim, M.-C. Pandolfino, Y. Guilloux, A. Khammari, C. Rabu, K. Echasserieau, F. Lang, M.-L. Gougeon, et al. 2005. Adoptive transfer of tumor-reactive Melan-A-specific CTL clones in melanoma patients is followed by increased frequencies of additional Melan-A-specific T cells. J. Immunol. 175: 4797-4805.
29. Bernhard, H., J. Neudorfer, K. Gebhard, H. Conrad, C. Hermanirn J. Nährig, F. Fend, W. Weber, D. H. Busch, and C. Peschel. 2008. Adoptive transfer of autologous HER2-specific cytotoxic T lymphocytes for HER2-overexpressing breast cancer. Cancer Immunol. Immunother. 57: 271-280.
30. Sergina, N. V., M. Rausch, D. Wang, J. Blair, B. Hann, K. M. Shokat, and M. M. Moasser. 2007. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445: 437-441.
31. Knutson, K. L., B. Almand, Y. Dang, and M. L. Disis. 2004. neu antigen-negative variants can be generated after neu-specific antibody therapy in neu transgenic mice. Cancer Res. 64: 1146-1151.
32. Singh, R., and Y. Paterson. 2007. Immunoediting sculpts tumor epitopes during immunotherapy. Cancer Res. 67: 1887-1892.
33. Czerniecki, B. J., G. K. Koski, U. Koldovsky, S. Xu, P. A. Cohen, R. Mick, H. Nisenbaum, T. Pasha, M. Xu, K. R. Fox, et al. 2007. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res. 67: 1842-1852.
34. Jonuleit, H., U. Kuhn, G. Müller, K. Steinbrink, L. Paragnik, E. Schmitt, J. Knop, and A. H. Enk. 1997. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur. J. Immunol. 27: 3135-3142.
35. Neudorfer, J., B. Schmidt, K. M. Huster, F. Anderl, M. Schiemann, G. Holzapfel, T. Schmidt, L. Germeroth, H. Wagner, C. Peschel, et al. 2007. Reversible HLA multimers (Streptamers) for the isolation of human cytotoxic T lymphocytes functionally active against tumor- and virus-derived antigens. J. Immunol. Methods 320: 119-131.
36. Konopitzky, R., U. König, R. G. Meyer, W. Sommergruber, T. Wölfel, and T. Schweighoffer. 2002. Identification of HLA-A*0201- restricted T cell epitopes derived from the novel overexpressed tumor antigen calcium-activated chloride channel 2. J. Immunol. 169: 540-547.
37. Fisk, B., T. L. Blevins, J. T. Wharton, and C. G. Ioannides. 1995. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J. Exp. Med. 181: 2109-2117.
38. + tumors. Cancer Res. 58: 4902-4908.
39. Meyer zum Buschenfelde, C., C. Hermann, B. Schmidt, C. Peschel, and H. Bemhard. 2002. Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restxicted HER2-specific T lymphocytes against HER2-overexpressing tumor cells. Cancer Res. 62: 2244-2247.
40. Lustgarten, J., M. Theobald, C. Labadie, D. LaFace, P. Peterson, M. L. Disis, M. A. Cheever, and L. A. Sherman. 1997. Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD. 8. Hum. Immunol. 52: 109-118.
41. Brossart, P., G. Stuhler, T. Flad, S. Stevanovic, H.-G. Rammensee, L. Kanz, and W. Brugger. 1998. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res. 58: 732-736.
42. Rongcun, Y., F. Salazar-Onfray, J. Charo, K.-J. Malmberg, K. Evrin, H. Maes, K. Kono, C. Hising, M. Petersson, O. Larsson, et al. 1999. Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. J. Immunol. 163: 1037-1044.
43. Anderson, B. W., G. E. Peoples, J. L. Murray, M. A. Gillogly, D. M. Gershenson, and C. G. Ioannides. 2000. Peptide priming of cytolylic activity to HER-2 epitope 369-377 in healthy individuals. Clin. Cancer Res. 6: 4192-4200.
44. Seliger, B., Y. Rongcun, D. Atkins, S. Hammers, C. Huber, S. Storkel, and R. Kiessling. 2000. HER2-/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes. Int. J. Cancer 87: 349-359.
45. *0201-binding affinity. J. Immunol. 167: 787-796.
46. Liu, G., H. Ying, G. Zeng, C. J. Wheeler, K. L. Black, and J. S. Yu. 2004. HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells. Cancer Res. 64: 4980-4986.
47. Brossart, P., S. Wirths, G. Stuhler, V. L. Reichardt, L. Kanz, and W. Brugger. 2000. Induction of cytotoxic T-lymphocytes responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 96: 3102-3108.
48. + patients with metastatic breast cancer. Clin. Cancer Res. 8: 3407-3418.
49. Knutson, K. L., K. Schiffman, M. A. Cheever, and M. L. Disis. 2002. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short lived peptide-specific immunity. Clin. Cancer Res. 8: 1014-1018.
50. + T cell repertoire against Her-2/neu antigens in neu transgenic mice is of low avidity with antitumor activity. Eur. J. Immunol. 34: 752-761.
51. Apostolopoulos, V., E. Yuriev, A. Ramsland, J. Halton, C. Osinski, W. Li, M. Plebanski, H. Paulsen, and I. McKenzie. 2003. A glycopeptide in complex with MHC class I uses the GalNAc residue as an anchor. Proc. Natl. Acad. Sci. USA 100: 15029-15034.
52. Vlad, A., S. Muller, M. Cudic, H. Paulsen, L. Otvos, F. Hanisch, and O. Finn. 2002. Complex carbohydrates are not removed during processing of glycopro-teins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells. J. Exp. Med. 196: 1435-1446.
53. Muller, M. R., F. Grünebach, A. Nencioni, and P. Brossart. 2003. Transfection of dendritic cells with RNA induces CD4- and CD8-mediated T cell immunity against breast carcinomas and reveals the immunodominance of presented T cell epitopes. J. Immunol. 170: 5892-5896.
54. Griinebach, F., K. Kayser, M. M. Weck, M. R. Muller, S. Appel, and P. Brossart. 2005. Cotransfection of dendritic cells with RNA coding for HER-2/neu and 4-1BBL increases the induction of tumor antigen specific cytotoxic T lymphocytes. Cancer Gene Ther. 12: 749-756.
55. Castilleja, A., D. Carter, C. L. Efferson, N. E. Ward, K. Kawano, B. Fisk, A. P. Kudelka, D. M. Gershenson, J. L. Muarray, C. A. O'Brian, and C. G. Ioannides. 2002. Induction of tumor-reactive CTL by c-side chain variants of the CTL epitope HER-2/neu protooncogene (369-377) selected by molecular modeling of the peptide: HLA-A2 complex. J. Immunol. 169: 3545-3554.
56. Vertuani, S., A. Sette, J. Sidney, S. Southwood, J. Fikes, E. Keogh, J. A. Lindencrona, G. Ishioka, J. Levitskaya, and R. Kiessling. 2004. Improved immunogenicity of an immunodominant epitope of the Her-2/neu protooncogene by alterations of MHC contact residues. J. Immunol. 172: 3501-3508.
57. Lustgarten, J., A. L. Dominguez, and C. Pinilla. 2006. Identification of cross-reactive peptides using combinatorial libraries circumvents tolerance against Her-2/neu-immunodominant epitope. J. Immunol. 176; 1796-1805.
58. Munz, C., R. Obst, W. Osen, S. Stevanovic, and H.-G. Rammensee. 1999. Al-loreactivity as a source of high avidity peptide-specific human CTL. J. Immunol. 162: 25-34.
59. deWitte, M. A., M. Coccoris, M. C. Wolkers, M. D. van den Boom, E. M. Mesman, J.-Y. Song, M. vanderValk, J. B. Haanen, and T. N. M. Schumacher. 2006. Targeting self-antigens through allogeneic TCR gene transfer. Blood 108: 870-877.
60. + T cells in humans. J. Exp. Med. 196: 207-216.
61. Mellinghoff, I. K., I. Vivanco, A. Kwon, C. Tran, J. Wongvipat, and C. L. Sawyers. 2004. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 6: 517-527.
62. Ito, Y-, T. Takeda, M. Sakon, M. Tsujimoto, S. Higashiyama, K. Noda, E. Miyoshi, M. Monden, and N. Matsuura. 2001. Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br. J. Cancer 84: 1377-1383.
63. Fuchs, I., N. Vorsteher, H. Buhler, K. Evers, J. Sehouli, G. Schalfer, and S. Kummel. 2007. The prognostic significance of human epidermal growth factor receptor correlations in squamous cell cervical carcinoma. Anticancer Res. 27: 959-963.
64. Memon, A. A., B. S. Sorensen, P. Meldegaard, L. Fokdal, T. Thykjaer, and E. Nexo. 2006. The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients. Br. J. Cancer 94:1703-1709.
65. Chien, K. R. 1999. Stress pathways and heart failure. Cell 98: 555-558.
66. Crone, S. A., Y.-Y. Zhao, L. Fan, Y. Gu, S. Minamisawa, Y. Lu, K. L. Peterson, J. Chen, R. Kahn, G. Condorelli, et al. 2002. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat. Med. 8: 459-465.
67. Herrmann, F., H.-A. Lehr, I. Drexler, G. Sutter, J. Hengstler, U. Wollscheid, and B. Seliger. 2004. HER-2/neu-mediated regulation of components of the MHC class I antigen-processing pathway. Cancer Res. 64: 215-220.
68. Kono, K., E. Sato, II. Naganuma, A. Takahashi, K. Mimura, II. Nukui, and J. Fujii. 2004. Trastuzumab (Herceptin) enhances class I-restricted antigen presentation recognized by HER-2/neu-specific Tcytotoxic lymphocytes, Clin. Cancer Res. 10:2538-2544.
69. Kayser, S., O. Watermann, C. Rentzsch, T. Weinschcnk, D. Wallwiener, and B. Guckel. 2003. Tumor-associated antigen profiling in breast and ovarian cancer: mRNA, protein or T cell recognition? J. Cancer Res. Clin. Oncol. 129: 397-409.
70. Weidanz, J. A., T. Nguyen, T. Woodburn, F. A. Neethling, M. Chiriva-Intemati, W. H. Hildebrand, and 3. Lustgarten. 2006. Levels of specific peptide-HLA class I complex predicts tumor cell susceptibility to CTL killing. J. Immunol. 177: 5088-5097.
71. Clay, T. M., M. C. Custer, J. Sachs, P. Hwu, S. A. Rosenberg, and M. I. Nishimura. 1999. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J. Immunol. 163: 507.
72. Morgan, R. A., M. E. Dudley, Y. Y. L. Yu, Z. Zheng, P. E. Robbins, M. R. Theoret, J. R. Wunderlich, M. S. Hughes, N. P. Restifo, and S. A. Rosenberg. 2003. High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and docs not alter the recognition of autologous melanoma antigens. J. Immunol. 171: 3287-3295.
73. Engels, B., E. Noessner, B. Frankenberger, T. Blankenstein, D. J. Schendel, and W. Uckert. 2005. Redirecting human T lymphocytes toward renal cell carcinoma specificity by retroviral transfer of T cell receptor genes. Hum. Gene Ther. 16: 799-810.
74. Xue, S.-A., L. Gao, D. Hart, R. Gillmore, W. Qasim, A. Thraser, J. Apperley, B. Engels, W. Uckert, E. Morris, and H. Stauss. 2005. Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene transduced human T cells. Blood 106: 3062-3067.
75. Sommermeyer, D., J. Neudorfer, M. Weinhold, B. Engels, E. Noessner, M. H. M. Heemskerk, D. J. Schendel, T. Blankenstein, H. Bemhard, and W. Uckert. 2006. Designer T cells by T cell receptor replacement. Eur. J. Immunol. 36: 3052-3059.
76. Morgan, R. A., M. E. Dudley, J. R, Wunderlich, M. S. Hughes, J. C. Yang, R. M. Sherry, R. E. Royal, S. L. Topalian, U. S. Kammula, N. P. Restifo, et al. 2006. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314: 126-129.